|
|
||||||||
Ann Thorac Surg 2000;70:391-395
© 2000 The Society of Thoracic Surgeons
a Sections of Thoracic Surgery, Hospital Mútua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain
b Oncology, Hospital Mútua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain
c Department of Pathology, Hospital Mútua de Terrassa, University of Barcelona, Terrassa, Barcelona, Spain
Address reprint requests to Dr Mateu-Navarro, Section of Thoracic Surgery, Hospital Mutua de Terrassa, Calle Sant Antoni 8-14, 08221 Terrassa, Barcelona, Spain
e-mail: 10838mmn{at}comb.es
Background. This study was undertaken to evaluate the technical feasibility and the sensitivity, specificity, and accuracy of remediastinoscopy in restaging N2 bronchogenic carcinoma treated with neoadjuvant chemotherapy.
Methods. Patients presenting mediastinal lymph node involvement at mediastinoscopy received three or four cycles of neoadjuvant chemotherapy with mitomycin, iphosphamide, and cisplatin or cisplatin and gemcitabine. If there was no disease progression, these patients underwent remediastinoscopy and, if no residual extracapsular involvement or N3 disease was found, a thoracotomy was then carried out.
Results. Twenty-four patients underwent remediastinoscopy. In 12 (50%) remediastinoscopy was positive. The 12 remaining patients were operated on and the tumors resected: 5 pneumonectomies and 7 lobectomies. Lymphadenectomy specimens showed residual disease in mediastinal lymph nodes in 5 patients (pN2) and hilar lymph nodes in 1 patient (pN1). The other 6 patients were free of nodal disease, and 4 of them presented no involvement at lung level either. The sensitivity, specificity, and accuracy of remediastinoscopy were 0.7, 1, and 0.8, respectively.
Conclusions. Remediastinoscopy is a technically feasible staging tool with high diagnostic accuracy that is useful in the selection of patients who can be served best by complete resection after neoadjuvant chemotherapy.
This article has been cited by other articles:
![]() |
F. J.F. Herth, J. T. Annema, R. Eberhardt, K. Yasufuku, A. Ernst, M. Krasnik, and R. C. Rintoul Endobronchial Ultrasound With Transbronchial Needle Aspiration for Restaging the Mediastinum in Lung Cancer J. Clin. Oncol., July 10, 2008; 26(20): 3346 - 3350. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. De Waele, M. Serra-Mitjans, J. Hendriks, P. Lauwers, J. Belda-Sanchis, P. Van Schil, and R. Rami-Porta Accuracy and survival of repeat mediastinoscopy after induction therapy for non-small cell lung cancer in a combined series of 104 patients Eur. J. Cardiothorac. Surg., May 1, 2008; 33(5): 824 - 828. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. E. Van Schil and M. De Waele A second mediastinoscopy: how to decide and how to do it? Eur. J. Cardiothorac. Surg., April 1, 2008; 33(4): 703 - 706. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Marra, L. Hillejan, S. Fechner, and G. Stamatis Remediastinoscopy in restaging of lung cancer after induction therapy. J. Thorac. Cardiovasc. Surg., April 1, 2008; 135(4): 843 - 849. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. De Leyn, D. Lardinois, P. E. Van Schil, R. Rami-Porta, B. Passlick, M. Zielinski, D. A. Waller, T. Lerut, and W. Weder ESTS guidelines for preoperative lymph node staging for non-small cell lung cancer Eur. J. Cardiothorac. Surg., July 1, 2007; 32(1): 1 - 8. [Abstract] [Full Text] [PDF] |
||||
![]() |
Z. Mansour, E. A. Kochetkova, X. Ducrocq, M.-D. Vasilescu, G. Maxant, A. Buggenhout, J.-M. Wihlm, and G. Massard Induction chemotherapy does not increase the operative risk of pneumonectomy! Eur. J. Cardiothorac. Surg., February 1, 2007; 31(2): 181 - 185. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. De Leyn, S. Stroobants, W. De Wever, T. Lerut, W. Coosemans, G. Decker, P. Nafteux, D. Van Raemdonck, L. Mortelmans, K. Nackaerts, et al. Prospective Comparative Study of Integrated Positron Emission Tomography-Computed Tomography Scan Compared With Remediastinoscopy in the Assessment of Residual Mediastinal Lymph Node Disease After Induction Chemotherapy for Mediastinoscopy-Proven Stage IIIA-N2 Non-Small-Cell Lung Cancer: A Leuven Lung Cancer Group Study J. Clin. Oncol., July 20, 2006; 24(21): 3333 - 3339. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J. Cerfolio, A. S. Bryant, and B. Ojha Restaging patients with N2 (stage IIIa) non-small cell lung cancer after neoadjuvant chemoradiotherapy: A prospective study J. Thorac. Cardiovasc. Surg., June 1, 2006; 131(6): 1229 - 1235. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Plat, P. Pierard, A. Haller, J. Hutsebaut, J. Faber, M. Dusart, P. Eisendrath, J-P. Sculier, and V. Ninane Endobronchial ultrasound and positron emission tomography positive mediastinal lymph nodes Eur. Respir. J., February 1, 2006; 27(2): 276 - 281. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. De Waele, J. Hendriks, P. Lauwers, P. Ortmanns, W. Vanroelen, A.-M. Morel, P. Germonpre, and P. Van Schil Nodal status at repeat mediastinoscopy determines survival in non-small cell lung cancer with mediastinal nodal involvement, treated by induction therapy Eur. J. Cardiothorac. Surg., February 1, 2006; 29(2): 240 - 243. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. DeCamp Jr., S. Ashiku, and R. Thurer The Role of Surgery in N2 Non-Small Cell Lung Cancer Clin. Cancer Res., July 1, 2005; 11(13): 5033s - 5037s. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Port, M. S. Kent, R. J. Korst, R. Keresztes, M. A. Levin, and N. K. Altorki Positron emission tomography scanning poorly predicts response to preoperative chemotherapy in non-small cell lung cancer Ann. Thorac. Surg., January 1, 2004; 77(1): 254 - 259. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. C.M. Pitz, K. W. Maas, H. A. V. Swieten, A. Brutel de la Riviere, P. Hofman, and F. M.N.H. Schramel Surgery as part of combined modality treatment in stage IIIB non-small cell lung cancer Ann. Thorac. Surg., July 1, 2002; 74(1): 164 - 169. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. Akhurst, R. J. Downey, M. S. Ginsberg, M. Gonen, M. Bains, R. Korst, R. J. Ginsberg, V. W. Rusch, and S. M. Larson An initial experience with FDG-PET in the imaging of residual disease after induction therapy for lung cancer Ann. Thorac. Surg., January 1, 2002; 73(1): 259 - 266. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| ANN THORAC SURG | ASIAN CARDIOVASC THORAC ANN | EUR J CARDIOTHORAC SURG |
| J THORAC CARDIOVASC SURG | ICVTS | ALL CTSNet JOURNALS |